Tim-3 finds its place in the cancer immunotherapy landscape
The blockade of immune checkpoint receptors has made great strides in the treatment of major cancers, including melanoma, Hodgkin’s lymphoma, renal, and lung cancer. However, the success rate of immune checkpoint blockade is still low and some cancers, such as microsatellite‐stable colorectal cancer...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-05-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/1/e000911.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172929718484992 |
|---|---|
| author | Catherine Sabatos-Peyton Ana Carrizosa Anderson Nandini Acharya |
| author_facet | Catherine Sabatos-Peyton Ana Carrizosa Anderson Nandini Acharya |
| author_sort | Catherine Sabatos-Peyton |
| collection | DOAJ |
| description | The blockade of immune checkpoint receptors has made great strides in the treatment of major cancers, including melanoma, Hodgkin’s lymphoma, renal, and lung cancer. However, the success rate of immune checkpoint blockade is still low and some cancers, such as microsatellite‐stable colorectal cancer, remain refractory to these treatments. This has prompted investigation into additional checkpoint receptors. T-cell immunoglobulin and mucin domain 3 (Tim-3) is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Coblockade of Tim-3 and PD-1 can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients. In this review, we will discuss the basic biology of Tim-3, its role in the tumor microenvironment, and the emerging clinical trial data that point to its future application in the field of immune-oncology. |
| format | Article |
| id | doaj-art-09b668cb292447a0b2347fc9ce188dc2 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-05-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-09b668cb292447a0b2347fc9ce188dc22024-11-09T00:45:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-05-018110.1136/jitc-2020-000911Tim-3 finds its place in the cancer immunotherapy landscapeCatherine Sabatos-Peyton0Ana Carrizosa Anderson1Nandini Acharya2Aff2 grid.418424.f0000000404392056Novartis Institutes for BioMedical Research, Inc. 02139 Cambridge MA USA3 The Gene Lay Institute of Immunology and Inflammation, Ann Romney Center for Neurologic Diseases, Harvard Medical School and Brigham and Women`s Hospital, Boston, Massachusetts, USA1 Department of Neurology, Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women`s Hospital, Boston, Massachusetts, USAThe blockade of immune checkpoint receptors has made great strides in the treatment of major cancers, including melanoma, Hodgkin’s lymphoma, renal, and lung cancer. However, the success rate of immune checkpoint blockade is still low and some cancers, such as microsatellite‐stable colorectal cancer, remain refractory to these treatments. This has prompted investigation into additional checkpoint receptors. T-cell immunoglobulin and mucin domain 3 (Tim-3) is a checkpoint receptor expressed by a wide variety of immune cells as well as leukemic stem cells. Coblockade of Tim-3 and PD-1 can result in reduced tumor progression in preclinical models and can improve antitumor T-cell responses in cancer patients. In this review, we will discuss the basic biology of Tim-3, its role in the tumor microenvironment, and the emerging clinical trial data that point to its future application in the field of immune-oncology.https://jitc.bmj.com/content/8/1/e000911.full |
| spellingShingle | Catherine Sabatos-Peyton Ana Carrizosa Anderson Nandini Acharya Tim-3 finds its place in the cancer immunotherapy landscape Journal for ImmunoTherapy of Cancer |
| title | Tim-3 finds its place in the cancer immunotherapy landscape |
| title_full | Tim-3 finds its place in the cancer immunotherapy landscape |
| title_fullStr | Tim-3 finds its place in the cancer immunotherapy landscape |
| title_full_unstemmed | Tim-3 finds its place in the cancer immunotherapy landscape |
| title_short | Tim-3 finds its place in the cancer immunotherapy landscape |
| title_sort | tim 3 finds its place in the cancer immunotherapy landscape |
| url | https://jitc.bmj.com/content/8/1/e000911.full |
| work_keys_str_mv | AT catherinesabatospeyton tim3findsitsplaceinthecancerimmunotherapylandscape AT anacarrizosaanderson tim3findsitsplaceinthecancerimmunotherapylandscape AT nandiniacharya tim3findsitsplaceinthecancerimmunotherapylandscape |